Adiponectin deficiency exacerbates cardiac dysfunction following pressure overload through disruption of an

Masayuki Shimano1, Noriyuki Ouchi, Rei Shibata

  • 1Whitaker Cardiovascular Institute, Boston University Medical Campus, Boston, MA, USA.

Insights

Adiponectin deficiency worsens heart failure after pressure overload by disrupting blood vessel formation. Restoring vascular endothelial growth factor (VEGF) improved heart function in knockout mice.

Area of Science:

  • Cardiovascular Biology
  • Molecular Cardiology
  • Angiogenesis Research

Background:

  • Adiponectin, an adipokine, is known for cardioprotective effects.
  • The role of adiponectin in coronary angiogenesis during pressure overload is unexplored.
  • Disrupted angiogenesis contributes to heart failure following cardiac stress.

Purpose of the Study:

  • To investigate the role of adiponectin in cardiac remodeling and angiogenesis under pressure overload.
  • To determine if adiponectin modulates adaptive angiogenesis via the AMPK/VEGF pathway.
  • To elucidate the mechanism by which adiponectin deficiency exacerbates heart failure.

Main Methods:

  • Utilized adiponectin-knockout (APN-KO) and wild-type (WT) mice subjected to transverse aortic constriction (TAC) for pressure overload.
  • Assessed cardiac function, hypertrophy, fibrosis, and capillary density post-TAC.
  • Measured expression of vascular endothelial growth factor (VEGF) and AMP-activated protein kinase (AMPK) phosphorylation.
  • Investigated the effects of AMPK inhibition and VEGF delivery in vivo and in cultured cardiac myocytes.

Main Results:

  • APN-KO mice showed exacerbated cardiac hypertrophy, fibrosis, and systolic dysfunction compared to WT mice after TAC.
  • Reduced myocardial capillary density and decreased VEGF/AMPK signaling were observed in APN-KO mice post-TAC.
  • AMPK inhibition worsened cardiac function and angiogenesis in WT mice, with diminished effects in APN-KO mice.
  • VEGF delivery reversed angiogenesis deficits and improved ventricular function in APN-KO mice.

Conclusions:

  • Adiponectin deficiency accelerates the progression to heart failure following pressure overload.
  • Adiponectin plays a crucial role in maintaining cardiac angiogenesis through the AMPK-dependent pathway.
  • Targeting the adiponectin-AMPK-VEGF axis may offer therapeutic strategies for pressure-overload-induced heart failure.

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
cAMP-dependent Protein Kinase Pathways01:25

cAMP-dependent Protein Kinase Pathways

Cyclic Adenosine Monophosphate (cAMP) is an essential second messenger that activates protein kinase A (PKA) and regulates various biological processes. A single epinephrine molecule binds to GPCR and activates several heterotrimeric G proteins, each stimulating multiple adenylyl cyclase, amplifying the signal, and synthesizing large numbers of cAMP molecules. Small changes in cAMP concentration affect PKA activity. The binding of four cAMP molecules induces a conformational change in PKA,...
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Imbalances in Cardiac Output01:26

Imbalances in Cardiac Output

The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send blood...
Cellular Adaptation II: Hypertrophy01:26

Cellular Adaptation II: Hypertrophy

Hypertrophy is the increase in the size of individual cells, resulting in the enlargement of a tissue or organ. Unlike hyperplasia, which involves an increase in cell number, hypertrophy is characterized by an increase in cell volume. This process often occurs in response to higher functional demand or hormonal stimulation, leading to the production of more structural proteins and organelles, thereby enhancing the cells' work capacity.There are two primary types of hypertrophy: physiological...